Two patients with chronic lymphocytic leukemia (CLL) can face very different futures. One may live for decades without ...

Targeted therapies may improve survival in these patients by concurrently managing immune dysregulation and the leukemic clone.

Expert Rev Hematol. 2013;6(4):441-449. The newest biological variables of prognostic relevance are useful for understanding the clinical heterogeneity of disease, however, their value at the time of ...

EHA June 2026 guidelines endorse time-limited first-line CLL therapy based on TP53 and IGHV, informed by CLL17 showing fixed-duration targeted therapy noninferior to continuous ibrutinib. MRD-guided ...

In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels continue their conversation on communicating ...

Treatment with so-called BTK inhibitors has improved the prognosis for people with chronic lymphocytic leukemia (CLL). At the same time, these drugs affect the immune system and may cause side effects ...

Medically reviewed by Archana Sharma, DO Key Takeaways Active surveillance, or watchful waiting, is often recommended for people with slow-growing CLL who do not have symptoms.Targeted therapies, such ...

In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and ...